Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Sorin Group has received the Japanese Pharmaceutical and Medical Devices Agency's approval to market its Stockert S5 Heart-Lung Machine in Japan.
Subscribe to our email newsletter
The Stockert S5 is the fifth-generation of heart-lung machines and the successor to Sorin Group’s SIII perfusion system. The company claims that the S5 technology sets new standards for safety, functionality and quality and will help hospitals achieve better patient outcome.
Michel Darnaud, president, Cardiopulmonary Business Unit and Intercontinental, Sorin Group, said: “With the launch of the new S5 in Japan, I am confident the Sorin Group will gain market leadership in heart-lung machines in this key country and further consolidate its leading worldwide market share.”